Topic Listing for ELAN CORP PLC

Aab-002 Acc-001
Acc-001 Active Immunotherapeutic Conjugate Vaccine Acc-001 Active Immunotherapeutic Conjugate Wyeth
Accompanying Notes Integral Part Financial Statements Accounting Records
Accrued Other Liabilities Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income Loss Acquired In-process Research Development Costs
Acquired Product Rights Finance Charges Actions Material Adverse Effect
Actions Necessary Change Rights Shareholders Additional Studies Bapineuzumab Active Immunotherapeutic Conjugate
Adopted Pursuant 906 Sarbanes-oxley Act 2002 Advancing Neuroscience Growing Business
Advertising Expenses Affiliate
Affirm Phase Monotherapy Trial Alan Gillespie Cbe Phd
Allison Hulme Phd Alpha Integrin
Alpha Integrin Tysabri Alzheimers Association
Alzheimers Disease Alzheimers Drug Discovery Foundation Addf
Alzheimers Other Neurodegenerative Diseases Alzheimers Research Development
Alzheimers Society Ireland Amarin Thomas Lynch
Amendment Amortized Revenue
Amortized Revenue Adalat Avinza An-1792 Prototype Active Vaccine
Analysis Results Operations Segment Analysis Segment
Ann Maynard Gray Annual Cash Incentive Bonus
Antigenics Antitrust Matters
Approaches Disrupting Beta Amyloid Cascade Approval Consolidated Financial Statements
Approved Profit Sharing Scheme Arrangements Former Directors
Asset Impairments Asset Impairments Write-off
Assets Measured Fair Value Non-recurring Basis Associates
Athena Notes Athena Notes-net Charge Debt Retirement
Audit Committee Audit Committee Financial Expert
Auditors Autoimmune Diseases
Autoimmune Diseases Research Development Available-for-sale Investments
Azactam Azactam Cease Exist
Azactam Maxipime Azd-103 Elnd-005
Bapineuzumab Aab-001 Bapineuzumab Aab-001 Aab-002 Wyeth
Basis Audit Opinion Basis Consolidation Presentation Financial Information
Basis Preparation Behalf Audit Committee
Behalf Ldcc Beta Amyloid Immunotherapies
Beta Secretase Biogen Idec
Biogen Idec Matter Biopharmaceuticals
Biopharmaceuticals Business Update Board
Board Committees Board Directors
Board Directors Senior Management Brendan Boushel
Business Business Combinations Intangible Assets Goodwill
Business Exposes Risks Environmental Liabilities Buying Patterns Wholesalers Distributors Cause Fluctuations Periodic Results
Buying Patterns Wholesalers Distributors Cause Fluctuations Quarterly Results Cambridge Dublin Ireland 2005
Capital Expenditures Capital Expenditures Investment
Cash Discounts Cash Equivalents
Cash Equivalents Liquid Capital Resources Cash Flows
Cash Flows Summary Cautionary Factors Affect Future
Certain Provisions Agreements Party Discourage Prevent Acquiring Shareholders Certification Pursuant 302 Sarbanes-oxley Act 2002
Certification Pursuant Usc 1350 Certification Pursuant Usc 1350 Adopted 906 Sarbanes-oxley Act
Change Control Changes Internal Control Over Financial Reporting
Charge Arising Guarantee Epil Noteholders Charge-backs
Chicago 8211 2008 Chief Executive Officers Statement
Code Ethics Collaboration Agreement Biogen Idec
Commercial Committee Commercial Success Bapineuzumab Other Potential Aip Products
Commitment Commitments Contingencies
Community Compensation Directors Officers
Competition Completion Recovery Plan
Compliance Statement Composition Leadership Development Compensation Committee
Conclusion Condensed Consolidated Interim Statement Comprehensive Income
Confidential Material Consent Independent Registered Public Accounting Firm
Consolidated Statement Total Recognised Gains Losses Contact
Contingencies Contingencies Relating Actual Potential Administrative Legal Proceedings
Contingencies Relating Actual Potential Administrative Proceedings Contract Revenue
Contractual Obligations Control Elan Subject Customary Exceptions
Convertible Debt Convertible Notes
Cost Sales Covenants
Credit Risk Creditors Amounts Falling Due Within
Critical Accounting Policies Crohns Disease
Current Economic Financial Crisis Material Adverse Effect Results Current Focus Operations
Current Investment Securities Current Liabilities
Current Operations Debt Facilities
Debt Instruments Debt Securities Current
Debtors Deferred Tax
Dennis Selkoe Depositary Adss
Depository Adss Derivative Financial Instruments
Derivative Instruments Development Marketing Collaboration Agreement Biogen Idec
Development Marketing Collaboration Agreements Directors
Directors Interests Directors Ordinary Shares
Directors Responsibilities Directors Secretarys Interests
Directors Secretarys Ordinary Shares Directors Service Contracts
Disclosure Controls Procedures Disposals Subsidiary Undertakings
Distribution Distribution Operating Loss Income Region
Distribution Operating Loss Region Divested Products
Divestments Documents Display
Donal Geaney Dublin Ireland 2005
Dublin Ireland 2008 Dublin Ireland 2009
Dublin Ireland 8211 2008 Dublin Ireland 8211 2009
Dublin Ireland Business Wire 2009 Dublin Ireland Cambridge 2005
Dublin Ireland Cambridge Mass 8211 2008 Dublin Ireland Chicago 8211 2009
Dublin Ireland Collegeville 8211 2007 Dublin Ireland Collegeville 8211 2009
Dublin Ireland Madison 8211 2008 Dublin Ireland San Diego 8211 2009
Dublin Ireland San Francisco New York 8211 2008 Dublin Ireland South San Francisco 8211 2009
Dublin Ireland Toronto Ontario 8211 2007 Dublin Ireland Toronto Ontario 8211 2008
Dublin Ireland Toronto Vienna Austria 8211 2009 Dublin Ireland-- Business Wire --march 2009
Dublin Ireland-- Business Wire 8212april 2009 Dublin Oct 2009 Business Wire
Duplicate Mailings Ebitda
Edt Edt Product Pipeline
Edts Business Strategy Effective 2005
Elan Elan Corporation Plc Schedule Valuation Qualifying Accounts Reserves
Elan Drug Technologies Elan Drug Technologies Business Update
Elan Subsidiaries Pro Forma Condensed Elans Parkinsons Research
Elans Patented Commercialized Nanocrystal Technology Eln
Elnd005 Aggregation Inhibitor Elnd005 Azd-103
Elnd005 Transition Employee Benefit Schemes Post-retirement
Employee Equity Purchase Plans Employee Savings Retirement Plan 401
Employees Enact-2 Phase Crohns Disease Maintenance Trial
Encore Phase Crohns Disease Trial Encore Study
Engage Enter Variety Transactions Adversely Affect Environment
Environmental Impact Epil Notes
Epil Waiver Fee Equity Price Commodity Risks
Equity Price Risk Equity Securities Current
Estimates Evaluating Tysabri Crohns Disease
Evaluating Tysabri Rheumatoid Arthritis Exact Name Registrant Specified Charter
Exceptional Exceptional Operating Income Expenses
Exchange Controls Other Limitations Affecting Security Holders Exchange Rate Risk
Exchange Risk Executive Committee
Executive Directors Basic Salary Executive Directors Pension Arrangements
Executive Officers Directors Remuneration Experience Expertise Patented Technology Portfolio
Experience Significant Delays Manufacture Products Supply Raw Materials External Appointments Retention Fees
External Research Collaborations Fail Comply Reporting Payment Obligations Medicaid Rebate Program
Fail Comply Reporting Payment Obligations Medicaid Rebate Programme Failure Consummate Strategic Transaction Favorable Terms Adversely Impact
Failure Consummate Strategic Transaction Favourable Terms Adversely Impact Failure Reintroduce Tysabri Market Substantial Delay Such Reintroduction
Fair Value Conversion Gain Fair Value Gain Conversion Option
Fair Value Measurements Fair Values
Fda Review Tysabri Treatment Fda Review Tysabri Treatment Multiple Sclerosis
Finance Charges Product Acquisition Accruals Finance Leases
Financial Asset Investments Impairment Financial Assets Impairment
Financial Calendar Financial Instruments
Financial Results Dividends Financial Risk Management
Financial Statements Financing Activities
Financing Costs Fixed Assets-financial Assets
Fixed Assets-intangible Assets Fixed Assets-tangible Assets
Floating Rate Notes Floating Rate Notes Due 2011
Floating Rate Notes Due 2013 Focus
Foreign Currencies Translation Subsidiary Associated Undertakings Foreign Currency Risk
Foreign Operations Form 20-f
Forward Contracts Forward-looking Statements
Future Success Depends Successful Development Commercialisation Tysabri Additional Future Success Depends Successful Development Commercialization Tysabri Additional
Gaap Information Gain Arbitration Award
Gamma Secretase Garo Armen
Garo Armen Phd General
Geographical Segments Going Concern
Goodwill Goodwill Other Intangible Assets
Goodwill Other Intangible Assets Impairment Goodwill Other Intangible Assets Property Plant Equipment Impairment
Goodwill Other Intangible Assets Tangible Fixed Impairment Government Regulation
Gross Profit Health Safety
Held Sale Assets Held Sale Assets Liabilities
Holders Ordinary Shares Executive Information Only Holder Honorable Richard Thornburgh
Hospital Business Products Immediate Release
Impairment Goodwill Other Intangible Assets Impairment Investments
Income Loss Before Tax Income Tax
Income Taxes Indenture
Indentures Independence Directors
Independent Auditors Report Index
Industry Markets Products Highly Competitive Information Contact
Information External Sources Intangible Assets
Intangible Assets Impairment Inter Alia
Interest Expense Interest Income
Interest Rate Risk Debt Interest Rate Risk Debts
Interest Rate Risk Investments Internal Control
International Financial Reporting Standards Internet Website
Introduction Inventory
Investing Activities Investment Gains
Investment Gains Losses Investment Losses
Investment Securities Impairment Investments
Investments Marketable Investment Securities Impairment Investments Non-consolidated Subsidiaries
Investor Relations Irish Capital Acquisitions Tax
Irish Stamp Duty Ivan Lieberburg Phd
John Groom Johnson Transaction
Judgment Against Karen Kim
Kathleen Martorano Kelly Martin
Kevin Mcintyre Kieran Mcgowan
Kyran Mclaughlin Lars Ekman
Lars Ekman Phd Laurence Crowley
Leadership Development Compensation Committee Leases
Leasing Legal Settlement
Legal Settlement Gain Legal Settlements Awards
Letter Agreement Liamdanielelancom
Limitations Right Own Shares Liquid Resources Shareholders Deficit
Liquidation Rights Liquidity Risk
List Litigation
Long Term Incentive Plan Lyons
Major Customers Managed Health Care Rebates Other Contract Discounts
Managed Healthcare Rebates Other Contract Discounts Managements Annual Report Internal Control Over Financial Reporting
Manufacture Market Existing Products Manufacturing
Manufacturing Development Scale-up Expertise Manufacturing Revenue Royalties
Manufacturing Scale-up Activities Marketed Products
Material Amounts Money Material Reimbursements Penalties Sanctions Fines
Materially Adversely Affected Maxipime
Maxipime Azactam Maxipime Azactam Asset Impairment
Maxipime Azactam Intangible Other Assets Impairment Media Relations
Medicaid Rebates Meetings
Members Elan Corporation Plc Memorandum Articles Association
Michael Fox Foundation Parkinsons Research Montreal Canada 8211 2008
Multiple Sclerosis Multiple Sclerosis Society Ireland Crohns Colitis Foundation America
Nanocrystal Technology Natalizumab
National Pain Foundation American Society Net Charge Debt Retirement
Net Charge Debt Retirements Net Gain Divestment Businesses
Net Gain Divestment Product Net Gain Divestment Products Businesses
Net Gain Sale Businesses Net Income Loss
Net Interest Net Interest Expense
Net Interest Investment Gains Losses Net Interest Investment Losses
Net Interest Other Expense Net Investment Gains
Net Investment Gains Losses Net Loss
Net Loss Adjusted Ebitda Net Loss Per Ordinary Share
Net Loss Per Share Net Loss Periods
Neurodegenerative Diseases New Accounting Pronouncements Not Yet Adopted
Nigel Clerkin Nominating Committee
Nominating Governance Committee Non-current Investment Securities
Non-current Liabilities Notes
Notice Annual General Meeting Now Therefore
Objects Operating Activities
Operating Expenses Operating Leases
Opinion Oral Controlled Release Technology Platform
Oral Controlled-release Ocr Technologies Ordinary Business
Ordinary Resolution Ordinary Resolutions
Organizational Structure Other Adjustments
Other Autoimmune Diseases Research Development Other Biopharmaceuticals Products
Other Charges Other Charges Credits
Other Current Assets Other Indications Tysabri
Other Matters Other Net Charges Gains
Other Net Gains Charges Other Non-current Assets
Other Ordinary Activities Other Provisions Memorandum Articles Association
Other Significant Charges Other Significant Net Charges
Otherwise Obtaining Funds Necessary Meet Cash Needs Outlook Update
P1-180 Relationship Between Patient Dependence Caregiver Burden Alzheimer8217s Paragraph Litigation
Parkinsons Disease Parkinsons Institute Clinical Center
Parkinsons Research Part
Parties Passion
Patent Matters Patents Intellectual Property Rights
Patients Paul Breen
Payments Former Director Pensions
Pensions Other Employee Benefit Plans Periodic Results
Person Pervasive Patient Relevance
Pfizer Litigation Settlement Shareholder Sec Investigation Pharma Marketing
Pharmaceutical Industry Subject Anti-kickback False Claims Laws United Pharmaceutical Industry Subject Antikickback False Claims Laws United
Pharmaceutical Market Podium Presentation
Policies Political Donations
Post Balance Sheet Events Premium Shares
Prescribing Program Presentation Disclosure Financial Information
Presentation Financial Statements Prialt
Prialt Different Pain Treatment Prialt Intangible Asset Impairment
Prialt Treatment Severe Chronic Pain Principal Accountant Fees Services
Principal Risks Uncertainties Prior 2005
Product Acquisitions Alliances Product Approval
Product Pipeline Product Revenue
Product Revenue Biopharmaceuticals Business Product Revenue Edt Business
Products Property Plant Equipment
Property Plant Equipment Region Proven Innovation Poorly Water-soluble Compounds Nanocrystal Technology
Provision Benefit Income Taxes Provision Income Taxes
Provisions Provisions Related Sales Prior Periods
Purchase Royalty Rights Range Manufacturing Services
Raw Materials Product Supply Recently Issued Accounting Pronouncements
Reclassifications Recognition Deferred Tax Assets
Reconciliation Ifrs Gaap Reconciliation Operating Loss Net
Redosing Tysabri Clinical Trial Reduced
Registered Office Registrar Ordinary Shares
Reimbursement Reform Related Parties
Related Party Transactions Relations Shareholders
Remuneration Policy Report Audit Committee
Report Independent Registered Public Accounting Firm Report Leadership Development Compensation Committee
Represented Meeting Research Beta Amyloid Immunotherapy
Research Development Research Development Commercial Activities
Research Development Expenses Resolution
Resolutions Respective Responsibilities Directors Auditor
Respective Responsibilities Directors Auditors Responsibility
Restricted Cash Restricted Stock Units
Restrictive Covenants Debt Instruments Restrict Prohibit Ability Engage Restructuring Accrual
Results Results Bapineuzumab Phase Clinical Trial Presented International Conference
Results Operations Retained Loss
Retained Losses Revenue
Revenue Biopharmaceuticals Business Revenue Divested Products
Revenue Edt Business Revenue Marketed Products
Revenue Recognition Revenue Region Destination Customers
Revenue Retained Products Revenue-discounts Sales Returns Rebates Charge-backs
Review Development Business Richard Collier
Rights Preferences Dividends Attaching Shares Safe Harbor Forward Looking Statements
Safe Harbor Forward-looking Statements Safe Harbour Forward-looking Statements
Sale Businesses Continuing Operations Sale Products Businesses Continuing Operations
Sales Discounts Allowances Sales Returns
San Francisco New York Dublin Ireland 8211 2009 Science Technology Committee
Scientific Approach Scientific Approach Alzheimers Disease Related Disorders
Scope Review Secretase Inhibitor Research
Secretase Inhibitors Secretase Inhibitors Beta Gamma
Securities Exchange Act 1934 Securities Matters
Securities Registered Pursuant Act Securities Reporting Obligation Pursuant Act
Securities Tysabri Matters Securitised Investments
Segment Analysis Selected Financial Data
Selkoe Selling General Administrative
Selling General Administrative Expenses Selling General Administrative Expenses Sga
Selling General Administrative Sga Expenses Senior Management
Sentinel Phase Add-on Trial Service Contracts
Services Offer Clients Severance Relocation Exit Costs
Severance Restructuring Other Costs Severe Chronic Pain
Shane Cooke Share Capital
Share Option Plans Share Options
Share Price Volatile Result Substantial Losses Investors Purchasing Share-based Compensation
Share-based Payments Shareholder Litigation Sec Investigation
Shareholders Deficit Shareholders Funds
Signatures Significant Accounting Policies
Significant Conversions Significant Disposals
Significant Shareholdings Some Officers Directors Been Named Defendants Putative Class
Specialty Business Group Statement Directors Responsibilities
Statement Directors Responsibilities Respect Annual Report Financial Statements Stock Compensation
Stock Option Plans Stock Price Volatile Result Substantial Losses Investors Purchasing
Strategic Alternatives Subject Continuing Potential Product Liability Risks Cost Material
Subject Continuing Potential Product Liability Risks Harm Business Subject Extensive Government Regulation Adversely Affect Ability Bring
Subject Pricing Pressures Uncertainties Regarding Healthcare Reimbursement Reform Subsequent Events
Subsidiary Companies Subsidiary Undertakings
Substantial Cash Needs Not Successful Generating Otherwise Obtaining Substantial Future Cash Needs Potential Not Successful Generating
Summary Operating Performance Supplemental Guarantor Information
Table Contents Taxation
Taxation Capital Gains Dividends Taxation Corporate Income
Technology Terms
Title Class Total Assets
Total Assets Region Total Revenue
Trademarks Transactions Directors
Transactions Directors Executive Officers Transition
Transition Therapeutics Transition Therapeutics Inc
Tysabri Tysabri Financial Assistance Program
Tysabri Financial Assistance Programme Tysabri Natalizumab
Tysabri Prialt Tysabri Treatment Crohns Disease
Tysabri Treatment Multiple Sclerosis Tysabri-row
Tysabri-united States Tysabri-us
Unable Secure Enforce Patent Rights Trade Secrets Other Unique Scientific Opportunity
United States United States Securities Exchange Washington 20549 Form 20-f
Validated Platform Technologies Oral Controlled Release Nanocrystal Technology Variable Interest Rates Based Average Libor 2006
Voluntary Suspension Tysabri Vote Important
Whereas William Daniel
Witness Whereof World Pharmaceutical Market
Write-off Deferred Transaction Costs Wyeth
Wyeth Collaboration Agreement 
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki